Abivax SA’s American Depositary Shares are trading higher in a momentum-driven move as the market looks ahead to a key near-term catalyst: topline results from the Phase 3 ABTECT maintenance trial of obefazimod in moderate-to-severe ulcerative colitis, guided for late Q2 2026. With the calendar now in mid-April, traders appear to be positioning for that readout window and repricing optionality tied to durability-of-response data.

Abivax has framed the maintenance-trial topline as a major potential value inflection following previously disclosed positive induction results in its ABTECT program. A successful maintenance outcome would strengthen the durability narrative for obefazimod and could tighten the company’s path toward U.S. regulatory filings later in 2026, contingent on trial success.

ABVX has also benefited from a steady drumbeat of constructive Street commentary in recent months, including new coverage initiations and raised price targets. That backdrop can amplify day-to-day moves—especially for high-beta biotech names—when no single company-specific press release is driving the tape.

Investors will likely focus on (1) any update that narrows the maintenance-trial timing within late Q2 2026, (2) details on durability and safety that shape payer and physician adoption expectations, and (3) financing signals, given Abivax’s history of sizable capital raises to fund late-stage development.